Myeloma Today - Summer 2022

Volume 22 Number 3 Summer 2022

Myeloma Today A publication of the International Myeloma Foundation

New Frontiers in Myeloma Research Highlights from the 13th Annual Summit of the IMF’s International Myeloma Working Group PAGE 4

Also in this edition: } Myeloma Abstracts from ASCO and EHA: Overview of key myeloma clinical trials, new drugs, new combinations, and new approaches to relapsed disease PAGE 8

} NLB at the Annual Congress of the ONS: The IMF’s Nurse Leadership Board presents symposium on new drugs, regimens, and strategies for myeloma PAGE 10

This edition of Myeloma Today is supported by Amgen • Bristol Myers Squibb • Janssen Oncology • Karyopharm Therapeutics • Legend Biotech • Takeda Oncology

Connect. Be Informed. Take Charge.

UPDATED AND INTERACTIVE RESOURCES AT A GLANCE covid19.myeloma.org

videos.myeloma.org

The latest information on COVID-19 variants and vaccination for myeloma patients

infoline.myeloma.org

IMWG CONFERENCE SERIES:

Making Sense of Treatment

Brian G.M. Durie, MD

Contact the IMF InfoLine with your myeloma-related questions and concerns

Maria V. Mateos, MD

S. Vincent Rajkumar, MD

Leading myeloma experts discuss the myeloma therapy news from the 2022 IMWG Summit, and the annual conferences of the American Society of Clinical Oncology (ASCO) and the European Hematology Association (EHA). Watch Now

diversity.myeloma.org Diversity and inclusion are integral aspects of the myeloma community

medications.myeloma.org Learn about FDA-approved therapies for myeloma

BEST OF 2022 ASCO & EHA Webinar Dr. Brian G.M. Durie explains the key news from the 2022 annual conferences of ASCO and EHA that myeloma patients and care partners need to know. Watch Now

publications.myeloma.org •B ooklets that explain myeloma therapies and more •T ip cards on topics important to myeloma patients

support.myeloma.org Robin Tuohy rtuohy@myeloma.org

will help you find a multiple myeloma support group

•G uide to Myeloma Acronyms and Abbreviations •G uide to Myeloma Terms and Definitions •M yeloma Today Spring 2022 edition

Take advantage of the hyperlinks in Myeloma Today by signing up for the digital edition at subscribe.myeloma.org, where you can also sign up to receive alerts about IMF events, webinars, teleconferences, and advocacy actions, as well as our e-newsletter Myeloma Minute.

And engage with us on social media! /myeloma

@IMFMyeloma

A Message from the IMF Chairman & Chief Scientific Officer Dear Reader, What does the future hold for myeloma patients? When we consider “Key Myeloma Research Questions for 2022–2026,” as we did at the 2022 Annual Summit of the International Myeloma Working Group (see next page), hopes and challenges for the future come into strong focus.

The IMF continues to be resilient in its mission to improve the quality of life of myeloma patients while working toward prevention and a cure. Our mission has served patients for over three decades and it will continue to do so for decades to come.

Being flexible and adapting to changing times have always been trademark qualities of the IMF’s programs, and I am highly optimistic that the IMF will continue to guide the way forward – with deep insight and kindness, which are essential in considering every individual patient’s needs.

“Knowledge is power” has always been the IMF’s fundamental principle. Patient feedback has been key in establishing metrics and benchmarks for ongoing improvements in our patient education and support programs, and for achieving best results.

Additionally, the formation of a network of support groups across the U.S. and the Annual Support Group Leaders Summit have been instrumental in providing a venue for feedback and discussions.

Blueprint for success The IMF’s goal of helping patients in every way possible has never wavered. Working as an international organization, it was apparent to the IMF from the outset that options for diagnostic testing and treatment vary wildly. In translating educational information into multiple languages and holding patient seminars around the world, it has become clear that everything can be different – and not just the language! We are keenly aware that we must do more to help.

Knowing the plight of patients around the world has been transformative. This led to our decentralized model: one in which guidelines and support structures are adapted to fit local needs.

The reality of global inequities is a powerful truth. Limited access to treatment is very real when therapy options run out, or when they are never there in the first place. Making new therapies available through clinical trials, such as through the IMF’s Asian Myeloma Network, can provide access where it’s desperately needed.

The future is bright The introduction of many new immune therapies offers great hope. This optimism covers both improving overall survival outcomes and potentially achieving a cure for some patients. The next five years will see a steady increase in lengths of remissions.

Assessing which options and sequences are best will be a challenge, but these are good challenges to have!

Through the IMF’s Black Swan Research Initiative® (BSRI®), the IMF is strongly committed to continuing research to explore options for achieving both prevention and cure. A new understanding of the early evolution of myeloma being achieved by

the BSRI’s iStopMM (Iceland Screens Treats or Prevents Multiple Myeloma) can lead to intervention and prevention strategies to optimize patient outcomes.

In the search for a cure, the first results of the ASCENT clinical trial evaluating the use of the D-KRd “quadruplet” combination therapy in high-risk smoldering mulSusie Durie and Dr. Brian G.M. Durie tiple myeloma (HR SMM) will receive a joint 2019 Honorary Doctorate for Scientific Excellence be presented later this year. from the Vrije Universiteit Brussel Results will guide the next steps toward achieving long and sustained minimal residual disease (MRD)-negative remissions and potential cure. Hightechnology approaches, including artificial intelligence (AI) and CRISPR genome editing, as well as molecular techniques, will enhance what can be accomplished.

Key challenges In most countries, the primary challenge for myeloma patients is access to standard of care (SoC) diagnostics and treatments.

Access to newer therapies is either limited or lacking. It is urgent to explore all possible solutions so that all myeloma patients receive the treatment they need. Multiple new approaches are required for greater access to SoC therapies. The IMF’s Beyond Medicines’ Barriers Program is pursuing a plan for improving access to care globally, using real world data (RWD) and empowering patients with myeloma to become advocates for regulatory approvals.

New COVID-19 subvariants continue to arise and spread, illus­ trating that the pandemic is still an ongoing challenge for myeloma patients who are at special risk from infections. Despite vaccination and boosters, the risk of infection or re-infection is very real. Please check the IMF webpage covid19.myeloma.org for updated information.

In conclusion The IMF is here to help with your myeloma-related questions and concerns. We are committed to our mission and formula for success, and will continue to adapt to new challenges, as we continue to guide patients to the best possible outcomes while working hard toward prevention and a cure.

Dr. Brian G.M. Durie IMF Chairman Chief Scientific Officer

This free issue of Myeloma Today© (Volume 22, Number 3) is dated July 15, 2022. Myeloma Today© is a quarterly (Spring, Summer, Fall, and Winter) publication of the International Myeloma Foundation, located at 4400 Coldwater Canyon Avenue, Suite 300, Studio City, CA 91604 USA

1.800.452.CURE toll-free in USA and Canada 1.818.487.7455 worldwide

SUMMER 2022

3

Scientific & Clinical

13th Annual Summit of the IMF’s

Focus on early disease and frontline therapy, early and

By Dr. Brian G.M. Durie IMF Chairman of the Board Chief Scientific Officer

The 2022 Annual Summit of the IMF’s International Myeloma Working Group (IMWG) took place June 7–9 in Vienna, Austria.

The IMWG is the most prestigious organization for myeloma researchers from around the world. A collaborative initiative focused on improving outcomes for patients with myeloma, the IMWG’s mission is to identify, support, and implement the most promising research to prevent the onset of active disease, to improve treatment, and to find a cure. Creating, supporting, and hosting the important work of the IMWG and its members is a critical element of the IMF’s commitment to expand myeloma research and to educate myeloma patients on a global level.

The IMWG Summit is a key annual activity for many of the world’s top myeloma experts who collaborate on imperative projects throughout the year. The 2022 event was the first in-person IMWG Summit in two years, and myeloma investigators and partners were very excited to be able to once again meet and discuss pressing questions face-to-face. Everyone was glad to exclaim, “We’re back!”

Every effort was made to achieve the usual schedule while ensuring everyone’s safety from COVID-19. Each day of the Summit, each participant had to test negative for COVID-19, and masks were required for participation in the formal meetings.

I am very pleased to report that no participant tested positive for COVID-19 during the IMWG Summit.

Key Takeaways The format for presentations at this year’s IMWG Summit was designed to accommodate more time for open discussions. This resulted in active and productive engagement from the participants. There were five plenary topics followed by four reports by the IMWG Working Committees.

4 SUMMER 2022

Early disease Sigurdur Kristinsson, PhD (University of Iceland, Reykjavík, Iceland) gave a presentation titled “Is Screening the Way to Go?” He summarized the results of the Black Swan Research Initiative® (BSRI®)-supported iStopMM (Iceland Screens Treats Or Prevents Multiple Myeloma) research project which has already screened more than 80,000 individuals.

The unexpected finding was that the screening not only identified monoclonal gammopathy of undetermined significance (MGUS), but it also found both smoldering multiple myeloma (SMM) and active myeloma. SMM turned out to be very common, with a prevalence of 0.5% in individuals aged 40 years and older. This means that early intervention could be offered to those with high-risk SMM (HR SMM), with excellent outcomes expected – possibly even a cure.

So is screening currently recommended? Although the study results look promising, the consensus is that we must await the outcome of the iStopMM randomized clinical trial to be able to assess improvements in overall survival (OS) and quality of life. It does seem that screening will be one way forward in 2026.

Bruno Paiva, PharmD, PhD (CIMA Universidad de Navarra, Pamplona, Spain) evaluated if simple and precise testing is needed to identify HR SMM. The answer is yes, with the incorporation of blood testing for the presence of circulating monoclonal plasma cells. With very sensitive testing, it is possible to use a precise cut-off of 0.015%. Less than this identifies patients with a very low likelihood of progression to active myeloma, and it is extremely important to exclude patients from unnecessary intervention.

María-Victoria Mateos, MD, PhD (University Hospital of Salamanca, Spain) discussed the results of various treatments for HR SMM. The aggressive CESAR clinical trial that is investigating a curative strategy for HR SMM with a combination of

info@myeloma.org myeloma.org

International Myeloma Working Group

later relapse, and the IMWG Working Committee activities Kyprolis® (carfilzomib) + Revlimid® (lenalidomide) + the steroid dexamethasone (KRd) as induction therapy, followed by autologous stem cell transplant (ASCT), consolidation with KRd, and maintenance with Rd. The trial produced excellent results, with only 3 out of 90 patients having disease progression to active myeloma after an average follow-up of more than 4 years.

Is simpler treatment using Revlimid alone also an option? Early data from ECOG clinical trial E3A06 are promising. As pointed out by S. Vincent Rajkumar, MD (Mayo Clinic, Rochester, MN), it will take very long follow-up to assess the full impact of treatments for HR SMM. This creates a dilemma for future planning and no consensus solution has been offered so far.

Minimal residual disease Jesús San Miguel, MD, PhD (CIMA Universidad de Navarra, Pamplona, Spain) chaired the session on assessing the current status of minimal residual disease (MRD) testing.

Alberto Orfao, MD, PhD (University of Salamanca, Spain) noted comparable information achievable, using either next-generation sequencing (NGS) and next-generation flow (NGF) testing methods with negativities at the 10 -5 to 10 -6 levels being the most important. Perhaps the most important new information is that the NGF test has been approved in Europe as “in vitro diagnostic directive” (IVDD)-compliant since Becton Dickinson took over the original commercial entity Cytognos. This means that NGF can be available at a cost of $100 to $200, which is much more manageable when compared to the NGS cost of $900 to $1,000.

Hervé Avet-Loiseau, MD, PhD (University Cancer Center of Toulouse, France) emphasized that the MRD endpoint should be considered as a “stand-alone” indicator to establish the best correlations, especially at the 10 -5 to 10 -6 levels of sensitivity. He did, however, note that in the CASSIOPEIA clinical trial, MRD negativity did not indicate a better outcome for patients with high-risk cytogenetics 17p- and/or t(4;14).

Dr. San Miguel, in his presentation, drew attention to the caution required linked to decisions for individuals identified as MRDpositive versus MRD-negative. Not only are there important technical difficulties which need to be standardized, but lowlevel MRD positivity can be linked to a good outcome. There is a need to identify such patients, perhaps on the basis of an MGUS-like phenotype on flow testing, which indicates a very good prognosis and, more importantly, no need for additional potentially toxic therapy.

Frontline therapy Dr. Rajkumar reviewed if sufficient data exist to indicate that the use of quadruplet (four-drug) therapy in the frontline setting is a standard of care (SOC). Although quadruplets such as Darzalex® (daratumumab) or Sarclisa® (isatuximab) plus Velcade® (bortezomib) + Revlimid + dexamethasone (VRd) or plus Velcade + thalidomide + dexamethasone (VTd) clearly produce a longer initial remission (progression-free survival, PFS), longer-term survival data are awaited.

Along the same lines, it was noted that the DETERMINATION clinical trial was presented as a plenary abstract at the recent American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, in which Paul G. Richardson, MD (Dana-Farber Cancer Institute, Boston, MA) discussed that PFS was significantly prolonged after early ASCT (versus delayed ASCT), but that overall survival (OS) is not impacted.

Thus, there are pros and cons to more intense initial treatment options – leaving very important considerations open such as patient choice, costs, convenience, and access in many healthcare systems.

Thierry Facon, MD (Centre Hospitalier Universitaire de Lille, France) emphasized that for non-transplant eligible patients, especially for the more elderly or frail, the triplet (three-drug) combination of Darzalex + Revlimid + dexamethasone (DRd), also called the (continues on next page)

top row, left to right:

Dr. Kenneth Anderson Dr. Sigurdur Kristinsson Dr. Thomas Martin Dr. Nikhil Munshi Dr. María-Victoria Mateos Dr. S. Vincent Rajkumar Dr. Paul Richardson bottom row, left to right:

Dr. Brian G.M. Durie

Dr. Bruno Paiva Dr. Thierry Facon Dr. Philippe Moreau Dr. Alberto Orfao Dr. Yi Lin Dr. Jesús San Miguel Dr. Mario Boccadoro

The plenary session at the 2022 Summit of the IMF’s International Myeloma Working Group in Vienna, Austria

1.800.452.CURE toll-free in USA and Canada 1.818.487.7455 worldwide

SUMMER 2022

5

Scientific & Clinical CONTINUED FROM PREVIOUS PAGE MAIA regimen, is very effective and well-tolerated and, perhaps, sufficient for the time being.

collaborative opportunities and improve our understanding toward achieving next-generation treatment choices.

Other discussants, Tom Martin, MD (University of California San Francisco, CA), Yi Lin, MD, PhD (Mayo Clinic, Rochester, MN), and Mario Boccadoro, MD (University of Turin, Italy) made additional important comments. First, if introduced early, CAR T-cell therapy and/or the use of bispecific antibodies may really improve both PFS and OS. Although this may be true, many cautions were raised about access, potential toxicities, and costs.

IMWG Working Committees

Overall, there was a sense that we need to await the outcomes of clinical trials such as CARTITUDE-5 and CARTITUDE-6, which are evaluating CAR T-cell therapy in the transplant-eligible and non-transplant-eligible patient populations.

In addition to the work of the smoldering myeloma and immune therapy teams, important work is being done in the following areas:

Bone disease An important innovation was the plan to establish a virtual computer database for imaging studies, to be based at Roswell Park Comprehensive Cancer Center in Buffalo, NY.

Mass spectrometry

This session, led by Philippe Moreau, MD, PhD (Nantes University Hospital, France), evaluated the impact of earlier use of important agents such as anti-CD38 monoclonal antibodies (e.g., Darzalex and Sarclisa). Choices include, and it seems will continue to include combinations with immunomodulatory agents, Blenrep® (belantamb mafodotin), bispecific antibodies, as well as a range of new novel agents.

An important project is to better understand the meaning and significance of low-level M-spikes detected by very sensitive mass spectrometry (MS, or “mass spec”) technology. It is likely that many low-level M-spikes are transient and a normal immune response to infections, but comprehensive studies are required, and these are already planned. Clearly, mass spec can detect and track monoclonal myeloma proteins, and at very low levels. This is a major step forward. We eagerly await a fully commercialized mass spec product.

Later relapse

In conclusion

Early relapse

This session, led by Nikhil Munshi, MD (Dana-Farber Cancer Institute, Boston, MA), included a future look by Kenneth Anderson, MD (Dana-Farber Cancer Institute, Boston, MA), and an evaluation of how to include a broader range of patients in clinical trials at later relapse stages, a summary of the new IMWG initiatives to establish an immune therapy database, as well as a virtual tissue biobank.

With a future-oriented perspective, Dr. Anderson emphasized the need to understand and treat immune defects in myeloma patients to have a chance to re-establish long-term disease control or cure. There was a consensus that these types of immune approaches will be crucial to achieving better, longer-term outcomes. There was also tremendous enthusiasm about the immune therapy database and virtual biobank which will provide

By any measure, the 13th Annual Summit of the IMWG was a wonderfully successful and productive event with lively interactions. All the participants took full advantage of the opportunities to connect face-to-face and to make plans for future research collaborations. MT

Please visit videos.myeloma.org to view IMWG Conference Series: Making Sense of Treatment as well as the helpful Ask Dr. Durie videos.

To read the Week in Review by Dr. Brian G.M. Durie blog series please visit blogs.myeloma.org.

Panel discussion with (left to right) Drs. Bruno Paiva, Sigurdur Kristinsson, Sagar Lonial, María-Victoria Mateos, Shaji Kumar, Brian G.M. Durie, and S. Vincent Rajkumar

6 SUMMER 2022

info@myeloma.org myeloma.org

The IMF Honors 2022 Research Achievement Awardees

Dr. Hervé Avet-Loiseau and Dr. Bruno Paiva

On June 8, the IMF presented this year’s Robert A. Kyle Lifetime Achievement Award and Brian G.M. Durie Outstanding Achievement Award at an in-person event at the 13th Annual Summit of the International Myeloma Working Group (IMWG) in Vienna, Austria. The Kyle and Durie Achievement Awards are presented each year to outstanding individuals who have made significant contributions in the field of myeloma research.

Robert A. Kyle Lifetime Achievement Award

Brian G.M. Durie Outstanding Achievement Award

The Robert A. Kyle Lifetime Achievement Award recognizes individuals whose work has resulted in significant advances in research, treatment, and care of myeloma patients. Dr. Kyle (Mayo Clinic, Rochester, MN) is a world-renowned myeloma expert whose groundbreaking research has led to the discovery of significant hematologic entities – monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM).

The Brian G.M. Durie Outstanding Achievement Award recognizes excellent achievements in myeloma research. Dr. Durie is the Chairman of the Board and Chief Scientific Officer of the IMF, the Chairman of the IMWG and the leader of the IMF’s Black Swan Research Initiative® (BSRI®), Professor of Medicine, and recipient of the Honorary Doctorate for Scientific Excellence from the Vrije Universiteit Brussel.

Dr. Hervé Avet-Loiseau (center) with recipients of the Robert A. Kyle Lifetime Achievement Award from prior years

This year’s recipient of the Robert A. Kyle Lifetime Achievement Award is Hervé Avet-Loiseau, MD, PhD. For a decade, Dr. AvetLoiseau has been Head of the Laboratory for Genomics in Myeloma at the University Hospital Center of Toulouse, France.

Since 2008, he has also served as the Head of the Hematology Laboratory at the University Hospital of Nantes, France.

Dr. Avet-Loiseau is the Chairman of Intergroupe Francophone du Myélome (IFM) and is highly involved in leading all biological studies.

This year’s recipient of the Brian G.M. Durie Outstanding Achievement Award is Bruno Paiva, PharmD, PhD. He is co-director of the Flow Cytometry Platform and co-director of the Monoclonal Gammopathies Research Laboratory at the CIMA Universidad de Navarra, Pamplona, Spain. With dedication to multidimensional flow cytometry analysis of hematological malignancies, Dr. Paiva is a key member of the i2TEAMM, which seeks U.S. Food and Drug Admin­ istration (FDA) and European Medicines Agency (EMA) approvals for MRD testing as a surrogate response endpoint in myeloma clinical trials. Dr. Paiva’s research laboratory has been at the core Dr. Bruno Paiva (center) with of more than 20 national and Dr. Jesús San Miguel, his mentor international clinical trials in at CIMA Universidad de Navarra, and Dr. Brian G.M. Durie, for whom myeloma and acute myeloid the prestigious award is named leukemia.

On the outstanding work of the Kyle and Durie Achievement Awardees, IMF Chairman of the Board and Chief Scientific Officer Dr. Durie has this to say: “We applaud their accomplishments and important contributions to improving the lives of myeloma patients.

We hope that they and their work inspire the researchers who attended the IMWG Summit to aim even higher, to help us understand and ultimately find a cure for this disease.”

IMF Patient, President & CEO Yelak Biru extended his warmest congratulations and appreciation to this year’s Kyle and Durie Achievement Awardees: “On behalf of the International Myeloma Foundation and patient communities worldwide, thank you for your scientific rigor and research to accelerate understanding of the biology of myeloma, and for your vast contributions to myeloma research.”

A musical performance by talented myeloma researchers has become a traditional part of celebrating the IMF’s Awardees

The 2022 IMF Research Achievement Awardees are honored by their colleagues during the 13th Annual Summit of the International Myeloma Working Group in Vienna, Austria

1.800.452.CURE toll-free in USA and Canada 1.818.487.7455 worldwide

SUMMER 2022

7

Scientific & Clinical

#W

DR S I E R HE

JOE

DETERMINATION and IFM 2018-04 clinical trials,

By Dr. Joseph Mikhael IMF Chief Medical Officer

The 2022 Annual Summit of the IMF’s International Myeloma Working Group (IMWG) is discussed by Dr. Brian G.M. Durie in this edition of Myeloma Today. In addition to the pivotal IMWG Summit, two other important annual meetings in the field of hematology and oncology took place in June 2022; the American Society of Clinical Oncology (ASCO) was held June 3–7 in Chicago and the European Hematology Association (EHA) was held June 9–12 in Vienna, Austria. This year, both ASCO and EHA annual meetings were held in hybrid format. This has been a remarkable year for myeloma research, with great work being done by investigators from around the world.

DETERMINATION clinical trial Only four of the most prominent abstracts (from ALL cancers) are selected to be presented at ASCO’s prestigious plenary session. Typically, the studies presented are large and practice-changing. This year, the final abstract of the ASCO plenary was the DETERMINATION clinical trial (abstract LBA4) presented

by Dr. Paul Richardson. I had the privilege of being the discussant, where an expert in the field puts the abstract into clinical context for the attendees. In this phase III study, patients were randomized to receive the triplet combination therapy of Velcade® (bortezomib) + Revlimid® (lenalidomide) + the steroid dexamethasone (VRd) as induction therapy, followed by transplant, then maintenance with Revlimid until disease progression vs. VRd with no transplant, followed by maintenance with Revlimid until disease progression.

The study met its primary endpoint of improved progression-free survival (PFS) in the transplant group. Patients who had a transplant stayed in remission 21 months longer than those who did not have a transplant, clearly demonstrating the ongoing benefit of transplant in myeloma. This also supports the use of long-term maintenance therapy with Revlimid.

However, when the overall survival (OS) was compared between the two study groups, it was essentially the same. So, although transplant patients stayed in remission longer, this did not translate into a survival advantage in the long term.

Published a few years ago, the Intergroupe Francophone du Myélome (IFM) clinical trial also demonstrated that transplant improved PFS but not OS, although nearly 80% of patients in the non-transplant arm in that study had a transplant at first relapse, suggesting that transplant can be done upfront or at first relapse. In the DETERMINATION study, only 28% of patients in the non-transplant arm had a transplant later – and there was still no OS advantage.

8

SUMMER 2022

Overview of Key ASCO So what does this mean? There are many opinions about this study and how necessary transplant really is in myeloma.

Transplant remains an important part of therapy, but it may not be required at frontline and could be considered at relapse.

Given the growing trend of increased treatment options in myeloma, one-size-fits-all no longer fits every patient. This further emphasizes the need for discussion between the healthcare team and the patient to decide what may be best for the individual patient.

Another important feature to the DETERMINATION clinical trial is that 19% of patients were of African descent – this is unprecedented in a large clinical trial in myeloma. Although African Americans comprise 20% of all myeloma patients in the United States, they are typically underrepresented in clinical trials, with an average of 8% – and often even lower in phase III studies.

As we seek to reduce the healthcare disparities in myeloma, this greater inclusion is more reflective of the true myeloma population and is to be commended.

IFM 2018-04 clinical trial Another study of note presented at ASCO was the IFM 2018-04 clinical trial (abstract 8002) evaluating the combination therapy of Darzalex® (daratumumab) + Kyprolis® (carfilzomib) + Revlimid + dexamethasone (D-KRd) in high-risk myeloma patients. Although there were only 50 patients in the study and the follow-up remains short, it is encouraging to see deep responses with this quadruplet approach in patients who typically have lower response rates and duration of response. This study also showed that we should plan on collecting stem cells after 3 cycles of D-KRd, as it was harder to collect stem cells after 6 cycles as initially planned. As more quadruplet therapies are being used in myeloma, this study will be helpful to guiding our choices in the frontline setting.

New agents, new combinations The majority of myeloma-related abstracts presented at both ASCO and EHA meetings included new agents and new combinations in relapsed disease. Blenrep® (belantamab mafodotin) is highly effective when given as monotherapy, but causes keratopathy in the majority of patients, many of whom experience dry eyes or reduced visual acuity. The DREAMM-5 clinical trial (abstract 8019) showed that when given with a gamma secretase inhibitor (nirogacestat), a lower dose of Blenrep results in less keratopathy but maintains the response rates. Other studies presented included the DREAMM-6 arm-A interim analysis of Blenrep in combination with Revlimid (abstract 8017) and the DREAMM-4 clinical trial with pembrolizumab (abstract 8018).

We will likely see Blenrep used in more combination therapies, following the trend of a drug proving itself as monotherapy, then validating its use in combination with other agents. info@myeloma.org myeloma.org

and EHA Abstracts

and new approaches to relapsed disease Arguably the most exciting area of research in myeloma right now is in CAR T-cell therapy, and we saw many advances discussed at ASCO and EHA, such as the following: 1. Making it “at home” (abstract S103) – There was a fascinating presentation at EHA of an academic center manufacturing CAR T cells themselves, without an outside industry partner. If centers could manufacture them locally, this could potentially herald greater access to CAR T-cell therapy. Interestingly, they were also able to provide a booster dose of CAR T cells, which may be able to prolong the benefit of the therapy.

2. Using it earlier (abstract S185) – Two types of CAR T-cell therapy have been approved by the FDA for myeloma patients who have had at least 4 prior lines of therapy.

Carvykti™ (ciltacabtagene autoleucel) is being evaluated in patients with 1–3 prior lines of therapy. The CARTITUDE-2 study data was updated to show that the very deep and durable responses we see in late-line therapies are now being reproduced in earlier settings.

3. Modifying the product – Manufacturing CAR T cells is a very complex process with many variables that can be altered to enhance it. One study (abstract 8005) produced CAR T cells much faster (in 3 days) but it still took several weeks for the process to be completed. Another study (abstract 8003) used a different method of manufacturing to potentially create a more durable CAR T-cell product.

4. Targeting new antigens (abstract 8004) – The two CAR T-cell products already approved by the FDA bind to B-cell maturation antigen (BCMA) on myeloma cells. Now CAR T cells are being developed that can bind to G proteincoupled receptor, class C group 5 member D (GPRC5D).

This may be particularly important when patients have previously been treated with a BCMA-targeting therapy.

 Talquetamab (abstract 8015) and RG6234 (abstract S180) are two bispecifics that target GPRC5D. Having multiple targets on the myeloma cell will likely improve our ability to control myeloma for longer periods of time.  Several clinical trials are exploring combinations of bispecifics with other drugs, with even a prospect of using two bispecifics together. This will continue to expand the options we will have for our patients in the coming years.

Many other studies are demonstrating the incredible research being conducted in myeloma. New agents like iberdomide (abstract P865) and modakafusp (abstract S181) might be available soon, while the FDA-approved anti-CD38 mono­clonal antibody Sarclisa® (isatuximab) is currently being developed for subcutaneous administration (abstract 8025).

It is both exciting and gratifying to see the sheer volume of myeloma studies, with many new drugs being developed at an incredible pace. We trust this will continue as we seek to find the cure for this awful disease and, until such time, to prolong the survival of patients with the best quality of life possible. MT Stay tuned for Dr. Mikhael’s next #WHEREISDRJOE column and contact the IMF InfoLine with your myeloma questions and concerns.

Until Labor Day, phone lines are open 9 a.m. to 4 p.m. (Pacific) Monday through Thursday, and until 2 p.m. on Fridays 1.800.452.CURE in the US and Canada or 1.818.487.7455 worldwide, or email InfoLine@myeloma.org to submit your query electronically.

2022 ASCO & EHA

30 video presentations by the experts!

In the prior edition of Myeloma Today, I explored the emerging treatment of bispecific antibodies. The pace of their development is striking as we saw abstracts updating us on many molecules:  Teclistamab (abstract 8007) is the most advanced bispecific agent. Updated results continue to show a response rate of approximately 60% in patients with heavily relapsed myeloma with side effects that are mostly predictable and manageable, including cytokine release syndrome (CRS).  Elranatamab (abstract 8006), another bispecific that targets BCMA, was studied to reduce CRS by using a step-up dosing strategy that may make the drug easier to give.

Visit asco.myeloma.org to view videos with leading myeloma researchers provided by the IMF team to keep you updated on the latest developments.

 REGN 5458 (abstract S189), another bispecific that targets BCMA, showed reduced rates of higher-grade CRS. 1.800.452.CURE toll-free in USA and Canada 1.818.487.7455 worldwide

SUMMER 2022

9

Nurse Leadership Board Kevin Brigle, PhD, NP Massey Cancer Center Virginia Commonwealth University Donna D. Catamero,

New Drugs, Regimens, and Strategies for Myeloma

Kathleen Colson, RN, BSN, BS Dana-Farber Cancer Institute

Nurse leaders reach 450 peers and impact the lives of 1000s of myeloma patients

Deborah Doss, RN, OCN Dana-Farber Cancer Institute

By Diane Moran IMF Senior Vice President, Strategic Planning

ANP-BC, OCN, CCRC

Myeloma Translational Research Mount Sinai Health System

Beth Faiman,

PhD, RN, MSN, APRN-BC, AOCN®, FAAN

Taussig Cancer Institute Cleveland Clinic Cancer Center Charise Gleason,

MSN, NP-BC, AOCNP®

Winship Cancer Institute of Emory University Michaela Hillengass, RN* Roswell Park Comprehensive Cancer Center *German certified

Tracy King, PhD, MN, RN Institute of Hematology Royal Prince Alfred Hospital Patricia A. Mangan, RN, MSN, APRN-BC

Abramson Cancer Center University of Pennsylvania Ann McNeill, RN, MSN, APN John Theurer Cancer Center Hackensack University Medical Center Teresa S. Miceli, RN, BSN, OCN William von Liebig Transplant Center Mayo Clinic – Rochester Kimberly Noonan, DNP, ANP-BC, AOCN®

Dana-Farber Cancer Institute Amy E. Pierre, RN, MSN, ANP-BC Memorial Sloan Kettering Cancer Center Tiffany Richards,

PhD, ANP-BC, AOCNP®

MD Anderson Cancer Center Sandra I. Rome,

On April 28, the IMF’s Nurse Leadership Board (NLB) members Beth Faiman, Kimberly Noonan, and Donna D. Catamero presented the “New Drugs, Regimens, and Strategies for Multiple Myeloma: Case Studies for Nurses” symposium at the 47th Annual Oncology Nursing Society (ONS) Congress held in Anaheim, California.

“This is the 16th year that the NLB nurses have held a symposium at the ONS Congress,” said Beth Faiman, a founding NLB member who chaired the symposium. “After two years of virtual meetings, we are delighted to see colleagues face to face. Nurses have been stretched thin and reconnecting at ONS helps us restore our energy so we can continue to deliver the very best care to our patients every day.”

Donna D. Catamero, Beth Faiman, and Kimberly Noonan

each patient has access to the latest treatments, clinical trials, and supportive care.”

Despite the pandemic-related challenges over the recent years, myeloma research has continued to progress. The ONS symposium is one of the ways the NLB helps nurses have the latest data that contributes to improved patient care.

Donna Catamero, who presented several cases of patients with relapsed myeloma, said, “Care of patients with relapsed myeloma has changed dramatically in recent years. We have a truly staggering number of options between the new drugs and new combinations available to our patients.

Ensuring that patient and caregiver preferences and concerns are included in treatment decision-making is more important than ever. As nurses, we can encourage and coach our patients in how to participate in the decision-making process.”

Kimberly Noonan, who presented the first case study at the symposium, said, “Myeloma is a cancer with significant disparities. Black Americans have higher rates of MGUS [a precancerous condition that can progress to myeloma] than we previously understood, but new research shows that Black patients achieve better outcomes when they receive equal therapy. Despite higher rates of myeloma, Black patients tend to have less biologically aggressive disease.” She continued, “As nurses, we want all our patients to achieve the best possible outcomes, and we can help achieve this by advocating for all our patients and ensuring that

The nurses noted that some patients are hesitant to discuss their priorities and concerns with their healthcare team. “Part of reducing disparities is ensuring that all patients are empowered to be engaged decision-makers with respect to their health,” added Kimberly. “As nurses, we need to tailor our approach and meet our patients where they are at. With a patient who is already feeling overwhelmed, heaping on more information is not an effective approach. We need to stick to the ‘must-know’ and, over time, we can move on to the ‘nice-to-knows.’ As we build the relationship with our patients, we encourage their questions and (continues on next page)

RN, MN, AOCN®, CNS

Cedars-Sinai Medical Center Mary Steinbach, DNP, APRN Huntsman Cancer Institute University of Utah Joseph D. Tariman,

PhD, RN, ANP-BC, FAAN

College of Science and Health De Paul University Daniel Verina,

DNP, RN, ACNP-BC

Mount Sinai Medical Center

The NLB symposium in progress at the 2022 ONS Congress

10 SUMMER 2022

info@myeloma.org myeloma.org

Advocacy

New Policies Aim to Support Cancer Research

By Robin Levy IMF Senior Director, Public Policy & Advocacy

on the Defense Advances Research Projects Agency (DARPA) to help accelerate research.

There are many new ideas in the cancer public policy space, with two proposals to help cancer patients being discussed most frequently: President Biden’s Cancer Moonshot initiative and the creation of a new agency known as ARPA-H.

The White House states that their intention with ARPA-H is to “make pivotal investments in breakthrough technologies and broadly applicable platforms, capabilities, resources, and solutions that have the potential to transform important areas of medicine and health for the benefit of all patients and that cannot readily be accomplished through traditional research or commercial activity.” Specifically, cancer is one of the diseases they aim to address through treatments, prevention tactics and, ultimately, cures.

Cancer Moonshot The Cancer Moonshot concept is not new. In 2016, Vice President Joe Biden led the Cancer Moonshot with the mission to accelerate the rate of progress against cancer. Now, President Biden has reignited the Cancer Moonshot and set a new national goal: “If we work together, we can cut the death rate from cancer by at least 50% over the next 25 years, and improve the experience of people and their families living with and surviving cancer.” To learn more about the Cancer Moonshot, visit whitehouse.gov/ cancermoonshot.

The IMF has been actively participating in working to shape these efforts. The IMF led the Coalition to Improve Access to Cancer Care (CIACC), a group of advocacy organizations, in sending a letter supporting the Cancer Drug Parity Act and sharing the importance of addressing access issues. You can view our letter at access2cancercare.org.

ARPA-H President Biden is proposing the establishment of the Advanced Research Projects Agency for Health (ARPA-H) in order to improve the U.S. government’s capabilities to speed research that can improve the health of all Americans. ARPA-H will support research that would provide transformative solutions for a range of diseases, including cancer and Alzheimer’s. ARPA-H will be modeled

The Health Subcommittee on Energy & Commerce (E & C) approved Subcommittee Chair Anna Eshoo’s bill authorizing ARPA-H. Additionally, the US Health and Human Services (HHS) Secretary Xavier Becerra announced that ARPA-H would be established administratively within the National Institutes of Health (NIH) as an independent entity. ARPA-H has the potential to produce innovative myeloma research in the future. As always, the IMF will work hard to ensure that the myeloma patient perspective is included in these and any other future programs and initiatives. MT

To learn more about our advocacy activities or to contact your legislators directly, visit advocacy.myeloma.org. To subscribe to the IMF Advocacy Newsletter, visit subscribe.myeloma.org. To learn more about how you can help, contact us at advocacy@myeloma.org.

We welcome your engagement, questions, and ideas.

NLB – CONTINUED FROM PREVIOUS PAGE gradually deepen their engagement. Part of the ONS Congress symposium is using the case studies to bring to life real-world best practices like shared decision-making.”

New therapies and clinical trial participation are areas that benefit from shared decision-making approaches. “In the past year, two CAR T-cell therapies have been approved, and the first bispecific antibody for myeloma may join them later this year. These advances are possible because of clinical trials,” said Donna, who has been involved with several studies. “Many myths and misconceptions exist about clinical trial participation. I discussed some of these during the ONS symposium. It is important for nurses to know the facts about clinical trials so they can communicate accurately with their patients. For example, some patients with myeloma worry that if they participate in a clinical trial, they could receive a placebo and not active treatment. This is not true. Patients in myeloma clinical trials would never receive less than the standard-of-care treatment. Misconceptions may cause patients to hesitate about clinical trial participation.”

lack of clinical trial participation may magnify disparities because clinical trials can provide early access to cutting-edge therapies.

Approximately 450 nurses attended the symposium and received nursing continuing education credits for their attendance.

Through these nurses, the NLB impacts the lives of 1000s of myeloma patients.

“Nurses are the linchpin of healthcare in the United States,” said Beth. “We are crucial to addressing disparities, effectively managing symptoms, and encouraging adherence to therapy.

Myeloma is becoming a chronic condition that is managed over multiple years and, over those years, our patients become our friends.” MT

Visit nlb.myeloma.org to learn how the NLB is improving the nursing care and self-care of patients with myeloma via publications, symposia, multimedia, and research.

The FDA says that people from racial and ethnic minorities, and other diverse groups, are underrepresented in clinical research which is concerning because people of different ages, races, and ethnicities may react differently to medical products. Furthermore, 1.800.452.CURE toll-free in USA and Canada 1.818.487.7455 worldwide

SUMMER 2022

11

Philanthropy

Investing in the Future: FreeWill

YOU can support the IMF mission through your legacy

By Lynn K. Green, Ed.D. IMF Senior Vice President, Philanthropy

The mission of the International Myeloma Foundation (IMF) is to improve the quality of life of myeloma patients while working toward prevention and a cure through four founding principles: Research, Education, Support, and Advocacy. Patients with myeloma and their loved ones are central to each IMF program and service. You are not alone. The IMF is here for you.

“The IMF was the first place where I felt that someone heard me and truly cared,” says Amy L. Salmon. “On Thanksgiving Day in 2016, at my sister-in-law’s house, I had an accidental fall.

There was a crack so loud that everyone in the room stopped what they were doing and looked at me. That was when the pain started, and it only got worse with each passing day for the next two years. First, I went without a diagnosis, then I was misdiagnosed. Life was hard. My teenage daughter had to grow up fast; she and my best friend were my only support system.

In 2018, my daughter brought me to the emergency room, and I told them I wasn’t leaving until they figured out what was wrong with me. Finally, I was seen by a specialist and my myeloma was diagnosed. I had tumors up and down my spine. For seven months, I was in the hospital receiving aggressive chemotherapy. I can’t even count the days I spent in the intensive care unit. Next, I was sent to a rehabilitation center to learn to walk again. After that, I was moved to a nursing home.

Transplant wasn’t an option because I don’t have a care partner. It took until May 2019 – a full year – to achieve remission; now I’m on maintenance therapy with Revlimid.

I found the IMF online and I was shown so much love. The IMF became my go-to resource and the knowledge I gained helps me have better conversations with my doctor. Now I want to be of help to others; I don’t want anyone to experience what I went through on my journey. Although I don’t have much and I may not understand the science of the research, I have faith that the IMF will find a cure for myeloma and, when that happens, I’ll be proud to have been even just a small part of it. This is why I decided to leave a legacy to the IMF through FreeWill.

I want to protect who and what I love.”

In one of the many initiatives by the IMF that support the myeloma community, we have partnered with FreeWill at freewill.com/myeloma, a secure and trusted online platform that can help you write your legal will in 20 minutes or less, at no cost to you. We know that making long-term decisions can be overwhelming. It is a sensitive undertaking for many families – especially for those dealing with myeloma.

12

SUMMER 2022

We never want to make anyone feel uncomfortable with these conversations. Our goal is to provide you with peace of mind, help you plan for the future, and ensure that your loved ones are protected.

FreeWill makes estate planning accessible to anyone – regardless of age or wealth.

This simple tool can help you secure your wishes for the future.

Plan for your assets, Amy L. Salmon dictate future healthcare decisions, and even make a gift to the causes you care about. If you prefer to finalize your estate planning with an attorney, making use of this resource first will save you time.

Finding a cure for myeloma is possible, and we would be honored to have you stand with us as we continue our steadfast search. Each and every day, we strive to make significant breakthroughs that will help us develop a deeper understanding of myeloma. While creating your plans for the future, you can make the IMF’s research, education, support, and advocacy a part of your personal legacy by including a planned gift in your will.

With your help, we can create a brighter and more hopeful future for the myeloma community. YOUR legacy could play a vital role in our search for a cure. Consider including us in your estate planning and becoming a philanthropic partner with the IMF today!

We know that life circumstances can change, and you may need to alter or reconsider your gift in the future. That’s all right – the IMF is and always will be here for you throughout your myeloma journey. MT For more information, please contact Lynn Green at 1.334.332.0888 or lgreen@myeloma.org. Visit myeloma.org/our-research to learn more about the IMF’s search for a cure, and discover how these myeloma research initiatives impact the cause. info@myeloma.org myeloma.org

International Partners

No Borders, No Barriers, No Limits

30 countries represented at the 2022 GMAN Summit!

Serdar Erdoğan IMF Director, GMAN and European & Middle Eastern Patient Programs

The 2022 Summit of the IMF’s Global Myeloma Action Network (GMAN) was launched on May 20 in Milan, Italy. Over 30 representatives of international organizations that serve the global myeloma community celebrated the opportunity to come together face-to-face for the first time since 2019. Under the evening sun, there were many emotional reunions of old friends separated by the COVID-19 pandemic, heartfelt greetings for those who had previously met only over video, and a very warm welcome for new members of GMAN. Celebration and hope were in the air as patients, their care partners, myeloma experts, and advocates shared their experiences with myeloma and discussed the advances in research made over the recent years.

GMAN is a group of individuals and organizations from around the world with the shared commitment of supporting the needs of the myeloma community. GMAN’s global mission is to improve the lives of myeloma patients, enhance the capabilities of patient advocacy groups, build the capacity of local myeloma organizations, and increase worldwide access to medicine and treatment. While each member organization Advocates at work during the has its own mission and vision, 2022 GMAN Summit GMAN works to convene members and partners to share best practices, address mutual areas of concern, and elevate awareness of myeloma.

Yelak Biru makes opening remarks at the 2022 GMAN Summit

Yelak Biru, IMF President & CEO, opened the Summit with a warm welcome and shared his goal of leading the IMF in its mission to improve lives and find a cure for myeloma using the model of Capacity Building, Awareness, and Improving Access.

He went on to outline the modern definition of resilience and the six domains that will help to advance the mission to cure myeloma and give patients and their care partners a framework for optimal balance.

Dr. Brian G.M. Durie, IMF Chairman & Chief Scientific Officer, spoke of the new era of myeloma therapy. As at every previous GMAN Summit, Dr. Durie’s presentation was eagerly anticipated and greatly appreciated. The progress in myeloma research has been truly dramatic, made possible thanks to the commitment of individuals who have joined clinical trials and undergone experimental therapies to provide the data that supports our expanding knowledge and understanding of myeloma. As Yelak expressed it, people are surviving far beyond expectation today because we stand on the shoulders of those who gave of themselves to make this possible.

Next, GMAN member organizations that received the 2021 Susie Novis Durie Grants shared the outcomes of their projects:

On May 21, the in-person participants of the GMAN Summit were joined by more of their peers via video. In all, 30 countries were represented! The GMAN community of patient organizations encircles the globe, from Australia to Finland, from South Korea to the United States.

 Austria’s Myelom Lymphom Hilfe Österreich presented “Fit despite cancer,” an online exercise program that supports quality of life through movement.  Portugal’s Associção Portuguesa Contra a Leucemia designed a website tool for patients and their care partners for directing questions to healthcare professionals. (continues on next page)

Myeloma patients, care partners, and advocates gather for the 2022 Summit of the IMF’s Global Myeloma Action Network (GMAN) in Milan, Italy

1.800.452.CURE toll-free in USA and Canada 1.818.487.7455 worldwide

SUMMER 2022

13

International Partners GMAN – CONTINUED FROM PREVIOUS PAGE  Croatia’s Mijelom CRO launched a drive to make clinical trials more accessible for patients in South-Eastern Europe.  Israel’s AMEN Association of Myeloma Patients created a program that supports Arabic myeloma patients in Israel in overcoming cultural and language barriers.

The recipients of the 2022 Susie Novis Durie Grants were announced: Myeloma Australia, Finland’s Suomen Syöpapotilaat, Norway’s Blodkreftforeningen, and Romania’s Myeloma Euronet.

We look forward to learning about their accomplishments at next year’s Summit.

Breakout sessions focused on starting and sustaining myeloma groups in new regions, as well as which GMAN working groups are needed. Robin Tuohy led a discussion on how to encourage people to remain committed to a support group even when they are in remission.

Dr. Mario Boccadoro and Dr. Joseph Mikhael led a panel discussion on CAR T-cell therapy in myeloma, and how to develop a strategy to overcome access and supply chain issues. The sessions finished with a review of new treatments for relapsed disease.

Importantly, the conversation about healthcare inequality was ongoing throughout the GMAN Summit. The issues of access to care, medications, and therapies can be compounded by issues with access to information and support. GMAN delegates shared experiences of myeloma therapies being approved in their countries but denied to patients because of lack of alignment with payers. GMAN is united in calling for all patients to have equal access to prescribed approved medications. A spirited discussion ensued around the definition of “required drugs” and whether in some areas this term is being used to limit myeloma patients to only first-line therapies.

Together, we explored the role of pharmaceutical companies in providing information and support, and how this differs from country to country. Some countries no longer have representation from the pharmaceutical industry. This led to a suggestion of a regional approach that would allow patients to get information and support from other countries, as well as their own. An idea was developed for stronger collaboration with the World Health Organization (WHO) to mandate use of drugs post-launch, and deeper relationships with industry to drive information and cost discussions. These discussions and suggestions serve to illustrate how patients, care partners, and advocates are eager not only to identify problems but to bring solutions to the table. We strive to bring “No Borders, No Barriers, No Limits” to life.

In closing, Yelak joined me in thanking the GMAN delegates for their engagement, collaboration, and passion for accomplishing our collective mission. MT

14 SUMMER 2022

info@myeloma.org myeloma.org

INTERNATIONAL MYELOMA FOUNDATION Founder Brian D. Novis

Founder Susie Durie

Board of Directors Chairman Dr. Brian G.M. Durie Christine Battistini Andrew Kuzneski, III Yelak Biru Dr. Robert A. Kyle Prof. Dr. Mario Boccadoro Prof. Dr. Heinz Ludwig Loraine Boyle Dr. Edith Mitchell Susie Durie Charles Newman Martine Elias Dr. S. Vincent Rajkumar George T. Hayum Matthew Robinson Jason Katz Benson Klein E. Michael D. Scott IMF Executive Team Yelak Biru President & Chief Executive Officer Dr. Brian G.M. Durie Chief Scientific Officer Jennifer Scarne Chief Financial Officer Diane Moran Senior Vice President, Strategic Planning Daniel Navid Senior Vice President, Global Affairs Lisa Paik Executive Vice President, Medical Affairs

Dr. Joseph Mikhael Chief Medical Officer Lynn K. Green, Ed.D. Senior Vice President, Philanthropy Mimi Choon-Quinones, PhD, MBA Senior VP, Global Advocacy, Access, Policy & Research Fatima Scipione Senior Vice President, Strategic Alliances and External Affairs Peter Anton Vice President, Marketing Robin Tuohy Vice President, Support Groups

IMF Staff Betty Arevalo Missy Klepetar Coordinator, InfoLine Inventory Control Manager Phil Lange Suzanne Battaglia Accountant Senior Director, Member Events Karla Lemus Nancy Bruno Assistant to Sr Director, Regional Director, Support Groups Member Events Sarah Chambliss Robin Levy Assistant Meeting Coordinator Senior Director, Kelly Cox Public Policy & Advocacy Director, Support Groups and Jason London Sr Dir, Regional Community Workshops Associate, MarCom & Web Danielle Doheny Jim Needham Director, Public Policy & Advocacy Publication Design Susie Durie Meghan O’Connor Director, Global Patient Initiatives Coordinator, Meetings & Programs Serdar Erdoğan Matthew Ohnsman Director, GMAN and European & Coordinator, Audio Visual Projects Middle Eastern Patient Programs Selma Plascencia Heather Fishman Director, Operations Donor Relations Annabel Reardon Jon Fitzpatrick Senior Director, Technology and Coordination, Strategic Program Management Support Groups Joy Riznikove Sherrie Guerrero Database Analyst Director, Human Resources Miko Santos Abigail Guzman Web Producer Meeting Registration & Guest Relations Kelley Sidorowicz Brenda Hawkes Regional Director, Support Groups Director, Development Brando Sordoni Paul Hewitt Accounting & Distribution Coordinator, InfoLine Rafi Stephan Kevin Huynh Assistant to the President & Web Specialist Chief Executive Officer Marya Kazakova Judy Webb Editor-in-Chief, Publications Coordinator, InfoLine Ilana Kenville Jonathan Weitz Assistant Director, Member Events Donor Relations

imfteam.myeloma.org

1.800.452.CURE toll-free in USA and Canada 1.818.487.7455 worldwide

SUMMER 2022

15

International Myeloma Foundation 4400 Coldwater Canyon Avenue, Suite 300 Studio City, CA 91604 USA myeloma.org 800.452.CURE

Printed in USA © 2022 International Myeloma Foundation. All rights reserved.

Change Service Requested

myeloma.org

Dedicated to improving the quality of life of myeloma patients while working toward prevention and a cure.

2022 IMF Calendar of Events Due to COVID-19 policies, adjustments to the calendar will be made as needed.

Aug 6

IMF Regional Community Workshop (RCW) East South Central – Virtual

Aug 20

IMF Patient & Family Webinar (PFW) – Virtual

Aug 25-27 International Myeloma Workshop (IMW) Annual Meeting – Los Angeles, CA Oct 1

IMF M-Power Community Workshop, New York City – Virtual

Oct 22

IMF Regional Community Workshop (RCW) East North Central – Virtual

Oct 29

IMF Patient & Family Webinar (PFW) – Virtual

Nov 19

IMF Regional Community Workshop (RCW) Pacific Northwest – Virtual

Dec 10-13 American Society of Hematology (ASH) Annual Meeting & Exposition – New Orleans, LA & Hybrid Dec 15

IMF Best of ASH Webinar for Patients and Caregivers – Virtual

LINK TO THE LATEST AT

events.myeloma.org

For information about international activities by IMF affiliates, please visit these websites:

Australia

myeloma.org.au

Canada

myelomacanada.ca

Israel

amen.org.il

Japan

myeloma.gr.jp

Latin America

mielomabrasil.org